Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Allergy Therapeutics plc

http://www.allergytherapeutics.com/

Latest From Allergy Therapeutics plc

Allergy Therapeutics Takes First Steps Into Broader Vaccine Field

Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.

Deals Immune Disorders

Anergis And Virometix Collaborate On Fast-Acting Allergy Immunotherapy

An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.

Deals Immune Disorders

Allergy Therapeutics: We’ve Learned From Our ‘Birch Mistakes’

Allergy Therapeutics says it has learned lessons from its failed Phase III birch pollen allergy trial and is applying those to its pivotal grass Phase III study.

Clinical Trials Commercial

Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register